New Drugs for Type 2 Diabetes: A Therapeutic Review

Update

A. List of included studies on second-line therapy


19. AstraZeneca. Comparison study of the glycemic effects, safety, and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes mellitus.


130. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, Angelo AD, et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2


226. Odawara M, Hamada I, Suzuki M. Efficacy and Safety of Vildagliptin as Add-on to


Diabetologia. 2006;49(3):442-51.


B. List of included cardiovascular studies


60. Pfister R, Cairns R, Erdmann E, Schneider CA. A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive


